Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.

Pollyea, Daniel A; Winters, Amanda; McMahon, Christine; Schwartz, Marc; Jordan, Craig T; Rabinovitch, Rachel; Abbott, Diana; Smith, Clayton A; Gutman, Jonathan A

Pollyea, Daniel A; Winters, Amanda; McMahon, Christine; Schwartz, Marc; Jordan, Craig T; Rabinovitch, Rachel; Abbott, Diana; Smith, Clayton A; Gutman, Jonathan A.

Affiliation

Pollyea DA; Division of Hematology, University of Colorado, Denver, USA.
Winters A; Division of Hematology, University of Colorado, Denver, USA.
McMahon C; Division of Hematology, University of Colorado, Denver, USA.
Schwartz M; Division of Hematology, University of Colorado, Denver, USA.
Jordan CT; Division of Hematology, University of Colorado, Denver, USA.
Rabinovitch R; Division of Hematology, University of Colorado, Denver, USA.
Abbott D; Division of Hematology, University of Colorado, Denver, USA.
Smith CA; Division of Hematology, University of Colorado, Denver, USA.
Gutman JA; Division of Hematology, University of Colorado, Denver, USA. jonathan.gutman@cuanschutz.edu.

Bone Marrow Transplant ; 57(2): 160-166, 2022 02.

Article de En | MEDLINE | ID: mdl-34645926

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Azacitidine / Leucémie aigüe myéloïde Type d'étude: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Bone Marrow Transplant Sujet du journal: TRANSPLANTE Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google